Navigation Links
SpectraScience Adds Industry Veteran to Executive Team
Date:6/16/2008

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical devices company today announced the appointment of its new Vice President of Sales, Christopher Jackson, who has held senior sales positions at Adeza Biomedical Specialty Laboratories, Medigene and most recently at Neomatrix, Inc.

"Chris brings to SpectraScience more than 24 years of sales and marketing experience in the medical device and lab services industries," said Jim Hitchin, CEO of SpectraScience. "We are excited to add Chris to our team and expect him to significantly impact our sales and marketing efforts. He has a demonstrated ability to grow sales for developing businesses. At Adeza, Chris was integral to expanding its sales force from 4 to 75 people, and from less than $750 thousand in sales to more than $44 million. His performance at the other firms he has worked with has been equally impressive. Bringing Chris on board gives our company a critical resource in helping us realize our vision of becoming the premier cancer screening device company in the marketplace."

Chris Jackson added "I am impressed with SpectraScience's technology and much of my decision to join the company is based on the opportunity to make a real impact in the cancer screening market with a more effective device."

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT(R) Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA clearance for sale in the U.S. and the CE Mark for the European Union, the WavSTAT system is the first commercially available product that incorporates this innovative and patented technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods currently available.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

Hayden Communications

Investor Relations

Todd Pitcher

(858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
11. Health Insurance Industry Contributions to Politicians Block Regulation, Affordability in Health Care Debate, Says FTCR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: